Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › North Carolina › Durham
Qorannoo klinikaalii Kansara Qara'a Non-Small Cell Durham, NC keessatti
Qorannoo 39 Kansara Qara'a Non-Small Cell f Durham fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Namoota walitti qabaa jiraSadarkaa 3
- Duke University Medical Center, Durham
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Namoota walitti qabaa jiraSadarkaa 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke University, Durham
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Exelixis Clinical Site #12, Durham
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Namoota walitti qabaa jiraSadarkaa 3
- UNC Lineberger Comprehensive Cancer Center ( Site 3250), Chapel Hill · Miili 10 fagaatti
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Namoota walitti qabaa jiraSadarkaa 3
- Durham VA Medical Center, Durham
- Duke University Medical Center, Durham
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Namoota walitti qabaa jiraSadarkaa 3
- Duke Cancer Center, Durham
A Study of PHN-012 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- PHN-012-001 Site, Durham
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Namoota walitti qabaa jiraSadarkaa 3
- UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · Miili 10 fagaatti
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Namoota walitti qabaa jiraSadarkaa 3
- Duke University Medical Center, Durham
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 2
- University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke Cancer Center Durham, Durham
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Namoota walitti qabaa jiraSadarkaa 3
- Clinical Study Site, Durham
- Clinical Study Site, Chapel Hill · Miili 10 fagaatti
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Namoota walitti qabaa jiraSadarkaa 3
- Durham VA Health Care System, Durham
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke University School of Medicine, Durham
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Namoota walitti qabaa jiraSadarkaa 2/3
- Duke University Medical Center, Durham
Effects of Infusion Timing on Treatment Response in Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill · Miili 10 fagaatti
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Namoota walitti qabaa jiraQorannoo ilaalaa
- UNC- Chapel Hill, Chapel Hill · Miili 10 fagaatti
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Namoota walitti qabaa jiraSadarkaa 1
- Duke Cancer Institute, Durham
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · Miili 10 fagaatti
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Namoota walitti qabaa jiraSadarkaa 1
- University of North Carolina - Gastroenterology and Hepatology, Chapel Hill · Miili 10 fagaatti
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke Cancer Institute, Durham
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2
- UNC Health - University of North Carolina, Chapel Hill · Miili 10 fagaatti
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Duke University Medical Center, Durham
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke Cancer Institute, Durham
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Duke Cancer Center, Durham
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Namoota walitti qabaa jiraSadarkaa 1
- Duke Cancer Institute /ID# 276267, Durham
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Research Site, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Namoota walitti qabaa jiraSadarkaa 1
- Research Site, Durham
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Duke Cancer Center /ID# 251975, Durham
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Durham VA Medical Center, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Duke Cancer Center, Durham
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2/3
- Durham VA Medical Center, Durham
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Namoota walitti qabaa jira
- Durham VA Medical Center, Durham, NC, Durham
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
Namoota walitti qabaa jiraSadarkaa jalqabaa 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
GEMINI-NSCLC: NSCLC Biomarker Study
Namoota walitti qabaa jiraQorannoo ilaalaa
- Duke University, Durham
- UNC, Chapel Hill · Miili 10 fagaatti
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Chapel Hill · Miili 10 fagaatti
A Study of NX-1607 in Adults With Advanced Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
Qorannoo Kansara Qara'a Non-Small Cell magaalota biroo keessatti
- Houston, TXQorannoo 145
- New York City, NYQorannoo 121
- Arlington, VAQorannoo 104
- Nashville, TNQorannoo 97
- Boston, MAQorannoo 90
- Los Angeles, CAQorannoo 87
- St. Louis, MOQorannoo 73
- Chicago, ILQorannoo 61
- Baltimore, MDQorannoo 60
- San Antonio, TXQorannoo 59
- Columbus, OHQorannoo 57
- Washington, DCQorannoo 55
Qorannoo biroo Durham keessatti
- Saree OljooQorannoo 64
- Saree (Gosoota Hunda)Qorannoo 58
- Myeloma Baay’eeQorannoo 37
- Leukemia Myeloidii HamaaQorannoo 33
- Kansara MetastatikiiQorannoo 33
- Kansarii ProstateQorannoo 32
- Dhibee QaraQorannoo 32
- Kansarii ColorectalQorannoo 28
- Kansarii OvariiQorannoo 27
- Luukemiya Limfoositiikii KeessummaaQorannoo 27
- Cufama OnneeQorannoo 26
- Kansarii PancreasQorannoo 24
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.